Page 7 - Immune Sciences News Today

Shares of Alpine Immune Sciences, Inc. (NASDAQ:ALPN – Get Free Report) have received an average rating of “Buy” from the six ratings firms that are currently covering the firm, MarketBeat reports. Six research analysts have rated the stock with a buy rating. The average 12-month price target among brokerages that have updated their coverage on […]

-- Enrollment in the phase 2 study of acazicolcept in systemic lupus erythematosus will be stopped to allow for early assessment of data -- -- Final analysis after last patient completes study...

Alpine Immune Sciences, Inc. (NASDAQ:ALPN – Get Free Report) insider James Paul Rickey sold 11,600 shares of the company’s stock in a transaction dated Thursday, December 14th. The stock was sold at an average price of $19.00, for a total transaction of $220,400.00. The sale was disclosed in a filing with the Securities & Exchange […]

Alpine Immune Sciences, Inc. (NASDAQ:ALPN – Get Free Report)’s stock price hit a new 52-week high during mid-day trading on Tuesday . The stock traded as high as $19.41 and last traded at $19.41, with a volume of 39483 shares changing hands. The stock had previously closed at $18.92. Wall Street Analyst Weigh In A […]

Alpine Immune Sciences, Inc. , a leading clinical-stage immunotherapy company focused on developing innovative treatments for autoimmune and inflammatory diseases, today announced that Mitchell Gold,...

Trexquant Investment LP acquired a new position in shares of Alpine Immune Sciences, Inc. (NASDAQ:ALPN – Free Report) in the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor acquired 42,773 shares of the biotechnology company’s stock, valued at approximately $440,000. Trexquant Investment LP owned 0.09% of […]

Alpine Immune Sciences, Inc. (NASDAQ:ALPN – Get Free Report) reached a new 52-week high on Monday . The stock traded as high as $16.33 and last traded at $16.02, with a volume of 747998 shares trading hands. The stock had previously closed at $15.63. Wall Street Analysts Forecast Growth Several equities analysts have recently weighed […]

ExodusPoint Capital Management LP bought a new position in shares of Alpine Immune Sciences, Inc. (NASDAQ:ALPN – Free Report) in the second quarter, HoldingsChannel reports. The firm bought 62,839 shares of the biotechnology company’s stock, valued at approximately $646,000. A number of other hedge funds and other institutional investors have also recently modified their holdings […]

Mustang Bio (NASDAQ:MBIO – Get Free Report) and Alpine Immune Sciences (NASDAQ:ALPN – Get Free Report) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their analyst recommendations, earnings, profitability, institutional ownership, dividends, valuation and risk. Valuation and Earnings This table compares […]